Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280231212186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Courtney S Pilkerton und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, West Virginia University, Morgantown, WV, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Obesity, Hemorrhage, Recurrence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Direct-acting oral anticoagulants (DOACs) have become the preferred drugs for managing venous thromboembolism (VTE). Despite their advantages over vitamin K antagonists such as warfarin, their use in obese patients remains controversial with many providers reluctant to switch patients managed on warfarin. Outcome research that opts to increase provider confidence when prescribing DOACs for patients with obesity will be invaluable.
Objective
This investigation evaluated whether patients with a body mass index (BMI) 35 kg/m 2 or greater who were prescribed a DOAC had a higher risk for a recurrent VTE or bleed event relative to warfarin.
Methods
The study was conducted in West Virginia which has the highest rate of obesity in the United States.
Results
Of the total study population (1633), 2.3% (37) had a recurrent thrombotic event, 5.5% (89) had a major bleed event, and 10.7% (174) had some type of bleeding event. No individual patient characteristic was associated with recurrent thrombosis—including BMI. Older age, antiplatelet use, and taking a medication with a theoretical risk of increasing the effect of DOACs were associated with any and major bleeding events. The use of warfarin was associated with major bleeding events more frequently versus a DOAC. Body mass index was not a predictor for recurrent VTE or any bleed or major bleed events.
Conclusions
These findings support the conclusion that DOACs are an appropriate and effective drug class for the management of VTE in patients with obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, West Virginia University, Morgantown, WV, USA.
- Cleveland Clinic Akron General, Akron, OH, USA.
- Naval Hospital Pensacola, Pensacola, FL, USA.
- St. Joseph's Medical Center, Buckhannon, WV, USA.
- Department of Clinical Pharmacy, West Virginia University, Morgantown, WV, USA.
- Community Care of WV, Buckhannon, WV, USA.
ORCID-Profile: Charles D Ponte, Amie M Ashcraft
Zitieren
APA
Pilkerton, C. S., Adelman, M., Crocetti, E., Xiang, J., Strick, V., Ponte, C. D., Peckens, S., Jackson, B. P., Whipp, K., & Ashcraft, A. M. (2024). Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231212186
Vancouver
Pilkerton CS, Adelman M, Crocetti E, Xiang J, Strick V, Ponte CD, et al. Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231212186
BibTeX
@article{Pilkerton2024,
author = {Pilkerton, Courtney S and Adelman, Megan and Crocetti, Emily and Xiang, Jun and Strick, Victoria and Ponte, Charles D and Peckens, Shaylee and Jackson, Benjamin P and Whipp, Kylen and Ashcraft, Amie M},
title = {Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280231212186}
}
EUVIMED